Genome-wide association studies of cognitive and motor progression in Parkinson's disease

Tan, Manuela M.X., Lawton, Michael A., Jabbari, Edwin, Reynolds, Regina H., Iwaki, Hirotaka, Blauwendraat, Cornelis, Kanavou, Sofia, Pollard, Miriam I., Hubbard, Leon, Malek, Naveed, Grosset, Katherine A., Marrinan, Sarah L., Bajaj, Nin, Barker, Roger A., Burn, David J., Bresner, Catherine ORCID: https://orcid.org/0000-0003-2673-9762, Foltynie, Thomas, Wood, Nicholas W., Williams-Gray, Caroline H., Hardy, John, Nalls, Michael A., Singleton, Andrew B., Williams, Nigel M. ORCID: https://orcid.org/0000-0003-1177-6931, Ben-Shlomo, Yoav, Hu, Michele T.M., Grosset, Donald G., Shoai, Maryam and Morris, Huw R. 2021. Genome-wide association studies of cognitive and motor progression in Parkinson's disease. Movement Disorders 36 (2) , pp. 424-433. 10.1002/mds.28342

Preview

PDF - Published Version Available under License Creative Commons Attribution. Download (1MB) | Preview

Abstract

Background There are currently no treatments that stop or slow the progression of Parkinson's disease (PD). Case–control genome‐wide association studies have identified variants associated with disease risk, but not progression. The objective of the current study was to identify genetic variants associated with PD progression. Methods We analyzed 3 large longitudinal cohorts: Tracking Parkinson's, Oxford Discovery, and the Parkinson's Progression Markers Initiative. We included clinical data for 3364 patients with 12,144 observations (mean follow‐up 4.2 years). We used a new method in PD, following a similar approach in Huntington's disease, in which we combined multiple assessments using a principal components analysis to derive scores for composite, motor, and cognitive progression. These scores were analyzed in linear regression in genome‐wide association studies. We also performed a targeted analysis of the 90 PD risk loci from the latest case–control meta‐analysis. Results There was no overlap between variants associated with PD risk, from case–control studies, and PD age at onset versus PD progression. The APOE ε4 tagging variant, rs429358, was significantly associated with composite and cognitive progression in PD. Conditional analysis revealed several independent signals in the APOE locus for cognitive progression. No single variants were associated with motor progression. However, in gene‐based analysis, ATP8B2, a phospholipid transporter related to vesicle formation, was nominally associated with motor progression (P = 5.3 × 10−6). Conclusions We provide early evidence that this new method in PD improves measurement of symptom progression. We show that the APOE ε4 allele drives progressive cognitive impairment in PD. Replication of this method and results in independent cohorts are needed. © 2020 The Authors.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine MRC Centre for Neuropsychiatric Genetics and Genomics (CNGG)
Publisher:	Wiley
ISSN:	0885-3185
Date of First Compliant Deposit:	11 November 2020
Date of Acceptance:	5 October 2020
Last Modified:	19 Sep 2024 01:25
URI:	https://orca.cardiff.ac.uk/id/eprint/136286

Citation Data

Cited 91 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item